This page has been archived.
Information identified as archived on the Web is for reference, research or recordkeeping purposes. It has not been altered or updated after the date of archiving. Web pages that are archived on the Web are not subject to the Government of Canada Web Standards. As per the Communications Policy of the Government of Canada, you can request alternate formats on the "Contact Us" page.
Name of Horizontal Initiative: Federal Initiative to Address HIV/AIDS in Canada (FI)
Name of Lead Department(s): Public Health Agency of Canada (the Agency)
Lead Department Program Activity: Disease and Injury Prevention and Mitigation
Start Date of the Horizontal Initiative: January 13, 2005
End Date of the Horizontal Initiative: Ongoing
Total Federal Funding Allocation (Start to End Date): Ongoing
Description of the Horizontal Initiative (Including Funding Agreement): The FI strengthens domestic action on HIV and AIDS, builds a coordinated Government of Canada approach, and supports global health responses to HIV and AIDS. It focuses on prevention and access to diagnosis, care, treatment and support for those populations most affected by HIV and AIDS in Canada—people living with HIV and AIDS, men who have sex with men, Aboriginal people, people who use injection drugs, federal inmates, youth, women, and people from countries where HIV is endemic. The FI also supports and strengthens multi-sector partnerships to address the determinants of health. It supports collaborative efforts to address factors which can increase the transmission and acquisition of HIV including sexually transmitted infections (STI) and also addresses co-infection issues with other infectious diseases (e.g., hepatitis C and tuberculosis) from the perspective of disease progression and morbidity in people living with HIV and AIDS. People living with and vulnerable to HIV and AIDS are active partners in Federal Initiative policies and programs.
Shared Outcome(s):
First level outcomes
Second level outcomes
Ultimate outcomes
Governance Structure(s):
The Responsibility Centre Committee (RCC) is the governance body for the FI. It is comprised of directors from the nine Responsibility Centres which receive funding through the FI. Led by the Agency, the RCC promotes policy and program coherence among the participating departments and agencies, and ensures that evaluation and reporting requirements are met.
The Agency is the federal lead for issues related to HIV and AIDS in Canada responsible for overall coordination, communications, social marketing, reporting, evaluation, national and regional programs, policy development, surveillance and laboratory science.
Health Canada (HC) supports community-based HIV and AIDS education, capacity-building, and prevention for First Nations on-reserve and Inuit communities south of the 60th degree parallel and provides leadership on international health policy and program issues.
As the Government of Canada's agency for health research, the Canadian Institutes of Health Research (CIHR) sets priorities for and administers the extramural research program.
Correctional Service Canada (CSC), an agency of the Public Safety Portfolio, provides health services (including services related to the prevention, diagnosis, care and treatment of HIV and AIDS) to offenders sentenced to two years or more.
Planning Highlights: In 2012–13, together with stakeholders, federal partners will strengthen their response on HIV and AIDS and other infectious diseases with new agreements to coordinate and deliver programs, research and services to prevent and control HIV and AIDS, other STBBI, and TB among First Nations, Inuit and Métis and other key priority populations. Content and related support for AIDS 2012 (Washington) and other key forums, and engagement with civil society and other stakeholders will advance policy priorities and technical responses to communicable diseases and broader public health issues. The coherence of national action to prevent and control HIV and AIDS and related communicable diseases will be increased through the 2012–2014 National HIV/AIDS Voluntary Sector Response Fund and other community based programming.
Federal Partner Program Activity | Names of Programs for Federal Partners | Total Allocation (from Start to End Date) | Planned Spending for 2012–13 | Expected Results for 2012–13 |
---|---|---|---|---|
Science and Technology for Public Health | HIV/AIDS Reference Testing and Quality Assurance | Ongoing | 3.1 | ER 1.1 ER 1.2 |
Surveillance and Population Health Assessment | Surveillance of Infectious Disease | Ongoing | 4.9 | ER 2.1 ER 2.2 |
Disease and Injury Prevention and Mitigation | Infectious Disease Prevention and Control and Community Associated Infections | Ongoing | 37.4 | ER 3.1 ER 3.2 ER 3.3 |
Total Agency | 45.4 |
Expected Results for 2012–13:
ER 1.1: Public health decisions and interventions are supported by timely, reliable and accredited reference service testing that accurately captures all the circulating HIV strains in Canada and directs attention to new outbreaks of HIV. This ensures effective identification and testing for emerging strains of HIV; enhance quality, reliability and comparability of HIV testing.
ER 1.2: Use of laboratory-generated knowledge is increased to: develop diagnostic, prognostic and drug resistance testing standards; provide quality assurance and performance standardization services for regional laboratories; determine changes in the patterns of HIV transmission; and reduce transmission of HIV from mothers to their infants through the identification of optimal and affordable antiviral therapies.
ER 2.1: Increased knowledge and awareness of risk behaviours to inform and guide the development of policies, prevention and care programs for key priority populations including populations in the North by pursuing the implementation of behavioural surveillance of Aboriginal populations (e.g. Yukon).
ER 2.2: Enhance national public health surveillance to address HIV and AIDS among specific ethno-cultural populations (people from countries where HIV is endemic) to contribute to existing surveillance prevention and other programmatic efforts for diseases related to migration by initiating work with federal and provincial partners on the surveillance of people from HIV endemic countries.
ER 3.1: Expanded evidence base, knowledge and awareness of the nature and methods to address HIV and AIDS in key priority populations, to inform ongoing research, policy initiatives and priorities; facilitate knowledge translation and exchange on the evidence linking communicable diseases and the determinants of health; and help identify promising and innovative community-based practices. Timely, reliable, and evidence-informed clinical recommendations for health care providers and public health professionals guide individual and population-based approaches for the detection and management of HIV infection and other related sexually transmitted infections (STIs). This includes upstream scientific evidence with respect to emerging HIV prevention technologies, HIV acquisition and transmission risk, and risks associated with co-infection, as well as primary care information and capacity for the screening, testing, treatment, and management of STIs.
ER 3.2: Enhanced engagement and collaboration on approaches to address HIV and AIDS with respect to Government of Canada policy and program development (domestic and international), and common communicable diseases prevention and control goals of First Nations, Inuit and Métis.
ER 3.3: Increased individual and organizational capacity to address HIV and AIDS.
Federal Partner Program Activity | Names of Programs for Federal Partners | Total Allocation (from Start to End Date) | Planned Spending for 2012–13 | Expected Results for 2012–13 |
---|---|---|---|---|
Internal Services | Governance and Management Support Services | Ongoing | 1.1 | ER 4.1 |
First Nations and Inuit Primary Health Care |
Bloodborne Diseases and Sexually Transmitted Infections — HIV/AIDS | Ongoing | 4.5 | ER 5.1 ER 5.2 |
Total HC | 5.6 |
Expected Results for 2012–13:
ER 4.1: Increased Canadian engagement and leadership in the global context through exchanging best practices with global partners. This will inform global and domestic policy discussion on HIV and AIDS in three global fora and promote policy coherence across the federal government's global activities on HIV and AIDS.
ER 5.1: Increased knowledge and awareness among First Nations, Inuit and/or Métis youth on the nature of HIV and AIDS and ways to address the disease. Determine effective evaluation approaches for sexual health promotion tools, evaluate the pilot Youth Messaging Initiative, and identify best practices related to wellness-type service delivery models in the provision of more holistic and comprehensive health services (HIV and other communicable diseases as well as mental health and substance abuse) to those at greatest risk.
ER 5.2: Enhanced engagement and collaboration on approaches to address HIV/AIDS through ongoing support to the International Indigenous Working Group on HIV/AIDS.
Federal Partner Program Activity | Names of Programs for Federal Partners | Total Allocation (from Start to End Date) | Planned Spending for 2012–13 | Expected Results for 2012–13 |
---|---|---|---|---|
Health and Health Services Advances | HIV and AIDS Research Initiative | Ongoing | 21.0 | ER 6.1 ER 6.2 ER 6.3 |
Total CIHR | 21.0 |
Expected Results for 2012–13:
ER 6.1: Increased knowledge and awareness of the nature of HIV and ways to address the disease through the development and administration of diverse HIV research funding programs. The funding programs will support biomedical, clinical and social science contributing to the development and evaluation of drugs, programs and services for people living with and at risk for HIV/AIDS. In 2012–13, new funding and funding programs will focus on the eradication of HIV, strengthening Canada's network of clinical investigators and addressing co-morbidities for people living with HIV in Canada.
ER 6.2: A strong and diverse HIV research community with the capacity to advance HIV research from biomedical science to community-based projects through support for training and salary award programs as well as multidisciplinary research networks.
ER 6.3: Enhanced coordination and strategic alignment of HIV research with national and international health research priorities and initiatives through the leadership and involvement of CIHR and Canadian researchers. Better coordination and strengthened partnerships will enhance resources for priority topics and help ensure effective application of new knowledge.
Federal Partner Program Activity | Names of Programs for Federal Partners | Total Allocation (from Start to End Date) | Planned Spending for 2012–13 | Expected Results for 2012–13 |
---|---|---|---|---|
Custody | Institutional Health Services Public Health Services | Ongoing | 4.2 | ER 7.1 ER 7.2 |
Total CSC | 4.2 |
Expected Results for 2012–13:
ER 7.1: Increased knowledge and awareness of the nature of HIV and AIDS and ways to address the disease, as achieved through: research and surveillance studies undertaken; tools and knowledge products developed and disseminated through publications, presentations and workshops; and as indicated by the percentage of federal offenders completing HIV and AIDS awareness programming.
ER 7.2: Enhanced engagement and collaboration on approaches to address HIV and AIDS and sexually transmitted and bloodborne infections through the Federal/Provincial/Territorial Heads of Corrections Working Group on Health and CSC's Community Consultation Committee on Public Health. The emphasis will be on developing and strengthening partnerships with: provincial and territorial governments; federal departments at national and regional levels; the Council of Chief Medical Officers of Health, and community partners.
Results to be Achieved by Non-Federal Partners (if Applicable): N/A
Contact Information:
Geneviève Tremblay
100 Eglantine Drive
Ottawa, ON K1A 0K9
613-952-7199
genevieve.tremblay@phac-aspc.gc.ca
Name of Horizontal Initiative: Preparedness for Avian and Pandemic Influenza Initiative
Name of Lead Department(s): Public Health Agency of Canada (the Agency)
Lead Department Program Activities:
Start Date of the Horizontal Initiative: June 21, 2006
End Date of the Horizontal Initiative: Ongoing
Total Federal Funding Allocation (Start to End Date): Ongoing
Description of the Horizontal Initiative (Including Funding Agreement): This initiative is directed at mitigating Canada's risk from two major, inter-related animal and public health threats: the potential spread of avian influenza (AI) virus (i.e., H5N1) to wild birds and domestic fowl in Canada; and, the potential for a human-adapted strain to arise resulting in human-to-human transmission potentially triggering a human influenza pandemic. A coordinated and comprehensive plan to address both avian and pandemic influenza is maintained.
The bulk of the initiative is ongoing. Activities have been launched in the areas of vaccines and antivirals, surge capacity, prevention and early warning, emergency preparedness, critical science and regulation, risk communication, and inter-jurisdictional collaboration. To enhance the federal capacity to address an on-reserve pandemic, efforts have been made to increase surveillance and risk assessment capacity to fill gaps in planning and preparedness.
Shared Outcome(s):
Immediate Outcomes
Intermediate Outcomes
Long-Term and Strategic Outcomes
Governance Structure(s):
In January 2008, the Agency, the Canadian Food Inspection Agency and Health Canada finalized the Avian and Pandemic Influenza Preparedness Interdepartmental/Agency Governance Agreement. The primary scope of the Agreement is the management of specific horizontal issues and/or initiatives relating to avian and pandemic influenza preparedness.
The Agreement is supported by a structure that falls within the auspices of the Deputy Minister's Committee on Avian and Pandemic Influenza Planning. Implementation of the Agreement is led by the Avian and Pandemic Influenza Assistant Deputy Ministers (API ADM) Governance Committee focusing on implementation of the initiatives. The API ADM Governance Committee provides strategic direction and oversight monitoring.
An Avian and Pandemic Influenza Operations Directors General Committee supports the API ADM Governance Committee, makes recommendations to it and oversees the coordination of deliverables.
Planning Highlights: In 2012–13 the collaborative efforts of the Agency, Health Canada and the Canadian Food Inspection Agency, will continue to clarify, communicate and test federal emergency management roles, responsibilities and mechanisms, with particular attention to the sustainability of response capacity and decision-making roles. These efforts will also improve the health portfolio's ability to communicate science to various audiences. Planned activities and expected results reflect lessons learned from the H1N1 pandemic, notably the Management Response and Action Plan (MRAP) following the Senate study.
Federal Partner Program Activity | Names of Programs for Federal Partners | Total Allocation (from Start to End Date) | Planned Spending for 2012–13 | Expected Results for 2012–13 |
---|---|---|---|---|
Science and Technology for Public Health | Rapid vaccine development and testing | Ongoing | 1.0 | ER 1.1 |
Winnipeg lab and space optimization | Ongoing | 13.2 | ER 1.2 | |
Surveillance and Population Health Assessment | Surveillance | Ongoing | 8.7 | ER 2.1 ER 2.2 |
Public Health Preparedness and Capacity | Vaccine readiness and clinical trials | Ongoing | 3.6 | ER 3.1 |
Capacity and Emergency Preparedness | Ongoing | 12.2 | ER 4.1 ER 4.2 ER 4.3 |
|
Laboratory network and communications capacity | Ongoing | 3.0 | ER 5.1 | |
Influenza research network |
Ongoing | 5.8 | ER 6.1 | |
Pandemic influenza risk assessment and modelling | Ongoing | 0.8 | ER 7.1 | |
Skilled national public health workforce | Ongoing | 5.9 | ER 8.1 | |
Regulatory Enforcement and Emergency Response | Contribution to National Antiviral Stockpile | Ongoing | 0.1 | ER 9.1 |
Total Agency | 54.3 |
Expected Results for 2012–13:
ER 1.1: Canada conducts relevant research to better understand influenza pathogenesis (how the virus produces disease), further interrogate the virus (antiviral susceptibility, vaccine effectiveness), develop possible vaccine candidates, and epidemiology (how the virus spreads) to mitigate impact and improve capacity against future pandemic influenza viruses.
ER 1.2: Construction of the 5,300-m2 new laboratory is completed; increased high importance research capacity.
ER 2.1: Respiratory and vaccine preventable diseases and vaccine safety are monitored and reported in a timely manner.
ER 2.2: Canada is able to identify, mitigate and control of disease transmission at the initial outbreak stage in order to reduce the potential impact of influenza epidemics and pandemics.
ER 3.1: Canada has access to a supply of pandemic influenza vaccine.
ER 4.1: Canada has access to a supply of antivirals.
ER 4.2: Canada is able to prepare for and anticipate risks associated with novel influenza strains.
ER 4.3: Canada has the capacity to carry out public health interventions including emergency response and a maintained state of readiness of the Health Portfolio's Emergency Operations Centre.
ER 5.1: Canada has the public health capacity (including infrastructure, technical expertise, training and stakeholder communications strategies) to prepare and respond to pandemic influenza.
ER 6.1: Canada has access to a rapid response research mechanism for pandemic influenza research questions.
ER 7.1: Predictive and assessment models used for pandemic preparedness are developed and established.
ER 8.1: The work of Public Health Officers at placement sites improves their skills and increases local and regional public health organizations' capacity to respond to health emergencies, while enhancing collaborative working relationships between stakeholders and PHAC.
ER 9.1: The National Antiviral Stockpile is maintained and plans are established for the replacement of antiviral stocks as they reach the end of their shelf-life.
Federal Partner Program Activity | Names of Programs for Federal Partners | Total Allocation (from Start to End Date) | Planned Spending for 2012–13 | Expected Results for 2012–13 |
---|---|---|---|---|
Health Products | Regulatory activities related to pandemic influenza vaccine | Ongoing | 1.2 | ER 10.1 |
Resources for review and approval of antiviral drug submissions for treatment of pandemic influenza | Ongoing | 0.2 | ER 11.1 | |
Establishment of a crisis risk management unit for monitoring and post-market assessment of therapeutic products | Ongoing | 0.3 | ER 12.1 | |
Health Infrastructure Support for First Nations and Inuit | Strengthen federal public health capacity through Governance and Infrastructure Support to FN/I Health System | Ongoing | 0.7 | ER 13.1 |
FN/I emergency preparedness, planning, training and integration | Ongoing | 0.3 | ER 14.1 | |
Specialized Health Services | Public health emergency preparedness and response (EPR) on conveyances | Ongoing | 0.2 | ER 15.1 |
Total HC | 3.0 |
Note: Totals may not add due to rounding
Expected Results for 2012–13:
ER 10.1: Policies, guidance and protocols are relevant for pandemic influenza; coordinated communications among jurisdictions with stakeholders and the public.
ER 11.1: Provision of timely, appropriate choice anti-virals and vaccines that meet the highest standards of safety, quality and efficacy.
ER 12.1: Timely and effective post-market monitoring and assessment of health products.
ER 13.1: Enhanced collaboration with Aboriginal Affairs, Northern Development Canada and the Public Health Agency of Canada as well as provincial/territorial partners on joint emergency preparedness and response (EPR) activities (including strengthening, testing and revising on-reserve First Nation pandemic plans). Strengthened links with key stakeholders to facilitate the integration of pandemic plans into all-hazards EPR plans.
ER 14.1: Continue to support the testing and revision of community pandemic plans based on H1N1 lessons learned.
ER 15.1: Coordination of policy and programs (including the emergency call system) for emergency preparedness and response related to pandemic influenza, quarantineable events and public health emergencies of international concern for conveyances, goods, cargo, and ancillary services.
Federal Partner Program Activity | Names of Programs for Federal Partners | Total Allocation (from Start to End Date) | Planned Spending for 2012–13 | Expected Results for 2012–13 |
---|---|---|---|---|
Animal Health and Zoonotics Program / Internal Services | Ongoing | 20.3 | ER 16.1 ER 16.2 ER 16.3 ER 16.4 ER 16.5 ER 16.6 ER 16.7 ER 16.8 ER 16.9 |
|
Total CFIA | 20.3 |
Expected Results for 2012–13:
ER 16.1: Increased human resource capacity to support risk mitigation procedures (such as enhanced screening of live birds or poultry products) at Canada's ports of entry.
ER 16.2: Enhanced stakeholder and the general public knowledge and awareness of the poultry industry service sector.
ER 16.3: Enhanced/integrated Canadian surveillance system to ensure timely identification of potential outbreaks and response to avian influenza situations. Targeted wild bird surveillance plan for 2012 is currently being reviewed.
ER 16.4: During inter-pandemic periods, strengthen regulatory capacity, utilize performance measurement tools to identify areas for improvement, and continue proactive and coordinated risk communications related to biosecurity and disease prevention.
ER 16.5: A trained, skilled and equipped workforce ready to respond to potential avian influenza and animal disease outbreaks.
ER 16.6: Improve, through investment in research, federal capacity for the control, risk assessment, diagnostics, modelling, and vaccine component of avian influenza issues to enhance evidence-based decision-making on avian influenza responses and the effectiveness of disease control measures to help mitigate risks to human health and economic loss.
ER 16.7: Continue to provide assistance to the World Organisation for Animal Health (OIE) Central Bureau in the Communications Department in an effort to promote the development and implementation of science based standards. CFIA continues to support the OIE's mandate and efforts to assist member countries in the control and eradication of animal diseases, including zoonotics, through its annual contribution to the OIE. In addition, the CFIA continues to support the development of capacity to address emergence of risk at the animal level through the Canadian chapter of Veterinarians Without Borders. Work continues to harmonize diagnostic approaches, response and market access related issues associated with AI.
ER 16.8: Maintaining, coordinating and managing the Canadian Animal Health Surveillance Network, an integrated network of federal, provincial and university labs. This network allows for rapid testing, detection and reporting of AI.
ER 16.9: Continued development of a viable response plan for avian influenza and animal disease outbreaks, including HR capacity, and data management tools.
Results to be Achieved by Non-Federal Partners (if Applicable): N/A
Contact Information:
Dr. John Spika
130 Colonnade Road
Ottawa ON K1A 0K9
613-948-7929
john.spika@phac-aspc.gc.ca
Name of Horizontal Initiative: Canadian HIV Vaccine Initiative
Name of Lead Department(s): Public Health Agency of Canada (the Agency)
Lead Department Program Activity: Disease and Injury Prevention and Mitigation
Start Date of the Horizontal Initiative: February 20, 2007
End Date of the Horizontal Initiative: March 31, 2017
Total Federal Funding Allocation (Start to End Date): $111 M
Description of the Horizontal Initiative (Including Funding Agreement): The Canadian HIV Vaccine Initiative (CHVI) is a collaborative undertaking between the Government of Canada (GoC) and the Bill & Melinda Gates Foundation (BMGF) to contribute to the global effort to develop a safe, effective, affordable and globally accessible HIV vaccine. This collaboration, formalized by a Memorandum of Understanding signed by both parties in August 2006 and renewed in July 2010, builds on the Government of Canada's commitment to a comprehensive, long-term approach to address HIV/AIDS. Participating federal departments and agencies are the Agency, Health Canada, Industry Canada, the Canadian International Development Agency, and the Canadian Institutes of Health Research.
The CHVI's overall goals are to: advance the basic science of HIV vaccine discovery and social research in Canada and low-and-middle-income countries (LMICs); support the translation of basic science discoveries into clinical research, with a focus on accelerating clinical trials in humans; address the enabling conditions to facilitate regulatory approval and community preparedness; improve the efficacy and effectiveness of HIV Prevention of Mother-to-Child (PMTCT) services in LMICs by determining innovative strategies and programmatic solutions related to enhancing the accessibility, quality, and uptake; and ensure horizontal collaboration within the CHVI and with domestic and international stakeholders.
Shared Outcome(s):
Immediate (1–3 years) Outcomes
Intermediate Outcomes
Long-Term Outcomes
Governance Structure(s):
The Minister of Health, in consultation with the Minister of Industry and the Minister of International Cooperation, is the lead Minister for the CHVI. An Advisory Board will be established and be responsible for making recommendations to responsible Ministers regarding projects to be funded and will oversee the implementation of the Memorandum of Understanding between the GoC and the BMGF. The CHVI Secretariat, housed in PHAC will continue to provide a coordinating role to the GoC and the BMGF.
Planning Highlights: CHVI-participating Departments and Agencies will further initiatives commenced in 2011–12. For example, improved domestic and international research projects, as well as the Alliance Coordinating Office will continue to be supported. Plans for 2012–13 include the completion of the development stage of the Discovery and Social Research Large Team Grants Funding Opportunity. The Government of Canada and the Bill & Melinda Gates Foundation will continue to work together to define areas of investment to accelerate the development of a safe, effective, affordable and accessible HIV vaccine as one of the key priorities.
Federal Partner Program Activity | Names of Programs for Federal Partners | Total Allocation (from Start to End Date) | Planned Spending for 2012–13 | Expected Results for 2012–13 |
---|---|---|---|---|
Disease and Injury Prevention and Mitigation | Infectious Disease Prevention and Control | 18.0 | 2.1 | ER 1.1 ER 2.1 ER 3.1 ER 3.2 |
Total PHAC | 18.0 | 2.1 |
Expected Results for 2012–13:
ER 1.1: Continue to support domestic and international efforts related to the research and development of an HIV vaccine.
ER 2.1: Develop an approach to access the HIV Vaccine Translational Support Fund to provide researchers with financial and project management support for translating HIV vaccine candidates from pre-clinical development research to small scale human clinical trials.
ER 3.1: Support the continued work of the Alliance Coordinating Office (ACO) to establish a strong and vibrant network of HIV vaccine researchers and other vaccine researchers both in Canada and internationally.
ER 3.2: Ensure effective communications, strategic planning, coordination, reporting and evaluation within the Government of Canada.
Federal Partner Program Activity | Names of Programs for Federal Partners | Total Allocation (from Start to End Date) | Planned Spending for 2012–13 | Expected Results for 2012–13 |
---|---|---|---|---|
Internal Services | Governance and Management Support Services | 1.0 | 0.1 | ER 4.1 |
Health Products | Regulatory Capacity Building Program for HIV Vaccines | 4.0 | 0.8 | ER 5.1 |
Total HC | 5.0 | 0.9 |
Expected Results for 2012–13:
ER 4.1: Increased regulatory convergence and exchange of domestic and international best practices, policies and protocols related to the regulation of vaccines, with a focus on HIV/AIDS vaccines.
ER 5.1: Increased regulatory readiness and strengthened capacity of regulatory authorities in LMICs in to the area of vaccine products and clinical trials through training and the establishment of a mentorship program.
Federal Partner Program Activity | Names of Programs for Federal Partners | Total Allocation (from Start to End Date) | Planned Spending for 2012–13 | Expected Results for 2012–13 |
---|---|---|---|---|
Commercialization and Research and Development Capacity in Targeted Canadian Industries | Industrial Research Assistance Program's Canadian HIV Technology Development Component | 13.0 | 2.5 | ER 6.1 |
Total IC | 13.0 | 2.5 |
Expected Results for 2012–13:
ER 6.1: New and innovative technologies for the prevention, treatment and diagnosis of HIV in pre-commercial development are advanced at small and medium-sized enterprises operating in Canada.
Federal Partner Program Activity | Names of Programs for Federal Partners | Total Allocation (from Start to End Date) | Planned Spending for 2012–13 | Expected Results for 2012–13 |
---|---|---|---|---|
Global Engagement and Strategic Policy | International Development Assistance Program | 60.0 | 13.3 | ER 7.1 ER 8.1 ER 9.1 ER 10.1 |
Total CIDA | 60.0 | 13.3 |
Expected Results for 2012–13:
ER 7.1: Increased capacity to conduct high-quality clinical trials of HIV vaccine and other related prevention technologies in LMICs through new teams of Canadian and LMIC's researchers and research institutions.
ER 8.1: In collaboration with CIHR, increased capacity and greater involvement and collaboration amongst researchers working in HIV vaccine discovery and social research in Canada and in LMICs through the successful completion of the development stage of the Team Grant program to support collaborative teams of Canadian and LMIC researchers.
ER 9.1: Increased number of women accessing high quality PMTCT services.
ER 10.1: Increased capacity of regulatory authorities in LMICs, especially those where clinical trials are planned or ongoing, through training and networking initiatives.
Federal Partner Program Activity | Names of Programs for Federal Partners | Total Allocation (from Start to End Date) | Planned Spending for 2012–13 | Expected Results for 2012–13 |
---|---|---|---|---|
Health and Health Services Advances | Institute Strategic Advances – HIV/AIDS | 15.0 | 2.9 | ER 11.1 ER 11.2 ER 11.3 ER 11.4 |
Total CIHR | 15.0 | 2.9 |
Expected Results for 2012–13:
ER 11.1: In collaboration with CIDA, increased research outcomes in discovery and social research in HIV vaccines through the successful implementation of CHVI Large Teams of Canadian and LMIC researchers.
ER 11.2: Greater support for new ideas, concepts, approaches and technologies in HIV by developing and launching funding opportunities in basic vaccine research.
ER 11.3: Increased cadre of young Canadian and LMIC vaccine researchers, through the development and launch of funding opportunities in vaccine research and ongoing support to funded CHVI large teams.
ER 11.4: Enhanced linkages and efficiencies amongst researchers funded within this initiative by promotion of mechanisms for networking and information sharing (such as data sharing platforms and global intellectual property access mechanisms) to support the production of new knowledge and the translation of research findings into improvements in health and the health care system.
Results to be Achieved by Non-Federal Partners (if Applicable): Non-governmental stakeholders (including research institutions and not-for-profit community organizations) are integral to the success of the CHVI. Their role is to engage and collaborate with participating departments and agencies, the Bill & Melinda Gates Foundation and other funders to contribute to the CHVI goals and to Canada's contribution towards the Global HIV Vaccine Enterprise.
Contact Information:
Marsha Hay-Snyder
200 Eglantine Driveway
Ottawa, Ontario K1A 0K9
613-957-1345
marsha.hay-snyder@phac-aspc.gc.ca